First City Capital Management Inc. Sells 1,000 Shares of Sanofi (NASDAQ:SNY)

First City Capital Management Inc. trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,620 shares of the company’s stock after selling 1,000 shares during the period. First City Capital Management Inc.’s holdings in Sanofi were worth $609,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lantz Financial LLC boosted its holdings in shares of Sanofi by 23.2% during the 2nd quarter. Lantz Financial LLC now owns 8,054 shares of the company’s stock valued at $391,000 after purchasing an additional 1,518 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Sanofi by 67.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 9,466 shares of the company’s stock worth $459,000 after purchasing an additional 3,815 shares during the period. Commonwealth Equity Services LLC raised its position in Sanofi by 1.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 166,308 shares of the company’s stock valued at $8,069,000 after purchasing an additional 3,092 shares in the last quarter. Aptus Capital Advisors LLC purchased a new position in shares of Sanofi during the second quarter valued at $205,000. Finally, Financial Counselors Inc. raised its holdings in shares of Sanofi by 22.4% in the second quarter. Financial Counselors Inc. now owns 10,835 shares of the company’s stock valued at $526,000 after acquiring an additional 1,984 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Down 0.2 %

NASDAQ SNY traded down $0.10 on Friday, hitting $48.09. 943,362 shares of the stock were exchanged, compared to its average volume of 1,090,078. The company has a market cap of $122.04 billion, a PE ratio of 24.54, a PEG ratio of 1.23 and a beta of 0.58. The company has a 50-day moving average price of $49.26 and a 200-day moving average price of $52.00. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.55 earnings per share. Sell-side analysts anticipate that Sanofi will post 4.06 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.